Electroporation-mediated Metformin for effective anticancer treatment of triple-negative breast cancer cells

In this research, we investigated the efficacy of Metformin, the most commonly administered type-2 diabetes drug for triple negative breast cancer (TNBC) treatment, due to its various anticancer properties. It is a plant-based bio-compound, synthesized as a novel biguanide, called dimethyl biguanide or metformin. One of the ways it operates is by hindering electron transport chain-complex I, in mitochondria, which causes a drop-in energy (ATP) generation. This eventually builds energetic stress and a decline in energy. Therefore, the natural cellular processes and proliferating tumor cells are obstructed. Here, we used electroporation, where, the MDA-MB-231, human TNBC cells were subjected to high intensity, short-duration electrical pulses (EP) in the presence of Metformin. The cell viability results indicate lower cell viability of 43.45 This indicates that Metformin, the most common diabetes drug could also be explored for cancer treatment.